论文部分内容阅读
目的 探讨甲亢患者13 1Ⅰ治疗前后临床缓解持续时间的长短及其骨密度的变化情况。方法 70例甲亢患者于13 1Ⅰ治疗前和其中 37例于13 1Ⅰ治疗后临床缓解小于 6个月、 9～ 12个月和大于 18个月分别用双能X线骨密度仪 (DEXA)进行骨密度 (BMD)测定 ,并分别与年龄匹配正常健康者 95例进行对照分析。结果 ①甲亢13 1Ⅰ治疗前和治疗后临床缓解早、中期L2 4BMD均明显低于正常对照组 ,差异有非常显著性 ,Ward’s区虽低于正常对照组 ,但差异无显著性 ;②13 1Ⅰ治疗后临床缓解后期L2 4及Ward’s区的BMD改善至接近正常人水平 ,差异无显著性 ;③13 1I治疗后临床甲低组L2 4及Ward’s区的BMD均明显低于正常对照组 ,差异有非常显著性。结论 甲亢经13 1Ⅰ治疗后临床缓解早、中期骨矿含量改善不明显 ,至后期逐渐增加接近正常对照组水平 ;13 1Ⅰ治疗后临床甲低持续时间大于 6个月者 ,同样会导致骨矿含量的降低。
Objective To investigate the changes of clinical remission duration and bone mineral density in patients with hyperthyroidism before and after treatment with 131I. Methods Seventy patients with hyperthyroidism were treated with 131 Ⅰ Ⅰ treatment and 37 of them were treated with 131 Ⅰ treatment. The clinical remission was less than 6 months. The patients with hyperthyroidism were treated with DEXA for 9 to 12 months and over 18 months. Density (BMD) determination, and were 95 cases of age-matched normal healthy controls were analyzed. Results ① The levels of L2 4BMD in hyperthyroidism before and after treatment were significantly lower than those in the normal control group before and after treatment, and the difference was significant. Although the Ward’s area was lower than the normal control group, there was no significant difference. ② After 131I treatment The BMD of L2 4 and Ward’s area in the late stage of clinical remission was improved to near normal level, but there was no significant difference between them. ③The BMD of L2 4 and Ward’s area of clinical hypothyroidism group were significantly lower than that of the normal control group . Conclusion The treatment of hyperthyroidism after 131I treatment of early and mid-term bone mineral content did not improve significantly, to gradually increase close to the normal control group level; 131I treatment of clinical hypothyroidism for more than 6 months, the same will lead to bone mineral content The reduction.